September 29, 2016 11:19 AM ET

Life Sciences Tools and Services

Company Overview of MerLion Pharmaceuticals Pte. Ltd.

Company Overview

MerLion Pharmaceuticals Pte. Ltd., a drug discovery and development company, engages in the research and development of natural products. It operates through two business units, MerLion Research and MerLion Development. The MerLion Research unit is a contract services business, which provides access to natural product collections by offering sample/extract supply services, extract profiling and standardization, assay development, throughput screening, compound purification and structural identification, biocatalyst isolation, and strain improvement. The MerLion Development unit is progressing finafloxacin, a differentiated antibacterial candidate through phase II clinical trials, which is ta...

1 Science Park Road

05-01 The Capricorn

Singapore Science Park II

Singapore,  117528


Founded in 2002


65 6829 5600


65 6829 5601

Key Executives for MerLion Pharmaceuticals Pte. Ltd.

Chief Executive Officer
Head of Research
Managing Director of MerLion Pharmaceuticals GmbH
Compensation as of Fiscal Year 2016.

MerLion Pharmaceuticals Pte. Ltd. Key Developments

MerLion Announces FDA Approval of Finafloxacin Otic Suspension

MerLion Pharmaceuticals announced that an otic suspension of finafloxacin has been approved by the FDA to treat acute otitis externa, commonly known as swimmer's ear, caused by Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin was licensed by MerLion to a major North American partner in 2010 for use in North America for otic (ear) infections. MerLion retains the rights to intravenous and oral formulations of finafloxacin for all other indications and recently announced positive results from a phase 2 trial conducted in Europe treating around 200 patients hospitalized with complicated urinary tract infections. The results from this study demonstrated positive outcomes at all primary and all secondary endpoints; with patients treated once daily for five days with finafloxacin seeing higher, more rapid and sustained level of microbiological eradication and improved clinical outcomes compared to those treated with the current standard of care (ciprofloxacin taken twice daily for 10 days).

Similar Private Companies By Industry

Company Name Region
1st BASE Pte Ltd Asia
Acumen Research Laboratories Pte Ltd. Asia
Cell Research Corporation Pte Ltd Asia
Curiox Biosystems Pte Ltd. Asia

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MerLion Pharmaceuticals Pte. Ltd., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at